Powder Delivery TRIZ Cases

Micronized bromocriptine particles address variable release by supporting rapid, consistent absorption through gastric and intestinal mucosa.

Bromide adsorption controls gold nanocube corner sharpness while surfactants and centrifugation support uniform, high-purity aggregates.

PEGMEMA and drug-bearing blocks form stable micelles that increase drug loading while reducing polymer dosage and side effects.

Photocleavable polymer-drug conjugates stay stable in the dark and release local anesthetic under light, limiting basal release and initial nerve block.

A synergistic polymeric biguanide and ammonium salt composition targets triazole-resistant Aspergillus while lowering biocide concentrations.

Poor solubility and rapid degradation challenge carmustine delivery; PLGA particles and surfactants support stability and reduce acute toxicity.

Conventional MANP formulations can lose stability during storage and transport; tuned excipients and pH limit aggregation and purity loss.

The EPC nanoparticle self-assembles without a separate carrier, addressing low drug loading and premature release while targeting EGFR-positive tumors.

Composite organic-inorganic scaffolds protect pH- and heat-sensitive agents while supporting controlled oral and mucosal release.

Natural and ionizable lipids form LPMP carriers that stabilize RNA encapsulation and support scalable mRNA vaccine production.

Poly-A particles restrain neutrophil migration and accumulation, addressing inflammatory lung damage in acute lung injury and ARDS.

Calcium carbonate protects probiotics during freeze-drying and storage while helping them withstand gastric and bile acids for intestinal reach.

Size exclusion chromatography separates freeze-thaw activated platelet vesicles by particle size for inhaled respiratory wound healing and inflammation relief.

Processing below 55°C through wet granulation, extrusion, and spheronization helps preserve antibody stability and activity in solid dosage forms.

Targeted salt aerosols deposit calcium or magnesium chloride near the larynx to hydrate tissue and reduce PTP within 15 minutes.

An amorphous nilotinib dispersion uses polymeric stabilization and optional organic acid to reduce food effects and impurity formation.

Uneven receptor expression drives off-target dumping; injury-site free radicals cross-link PEG conjugates for localized, sustained therapeutic presentation.

Existing probiotic studies showed limited quality-of-life effects; this strain modulates brain activity to reduce mental fatigue and improve stress coping.

Weak and toxic HIV-1 inhibitors are addressed with cyclic peptides that target CD4 and co-receptor sites on gp120.

Tert-butyl alcohol and a high sugar-to-protein ratio shorten reconstitution while preserving antibody formulation stability.

Dual inhibition of glutaminase and GSTP1 stabilizes ISCU, restores oxidative metabolism, and reduces endothelial-cell apoptosis in pulmonary hypertension.

D1 and Angiopep-2 conjugated gold nanorods cross the blood-brain barrier for sensitive, lower-dose CT detection of β-amyloid plaques.

Desiccant-protected dry powder surfactants address moisture-related stability constraints while avoiding endotracheal tube delivery.

Replacing the free base with milled alkali metal salts increases systemic exposure and bioavailability without added stabilizers.

Improved solubility in simulated lung fluid and bioavailability distinguish Crystal Form 2 from Form A for respiratory treatment.

Liquid at room temperature, the PMMA formulation gels at body temperature to remain in the spinal disc and limit leakage.

Direct inhalation delivers interferon-beta to respiratory cells, restraining viral replication for pre- and post-exposure prophylaxis.

Poorly water-soluble APIs are combined with hydrophilic polymers and surfactants to improve dissolution and reduce food-effect variability.

Acetic acid and pH 3–6 help stabilize RUC-4 formulations against chemical and physical degradation during storage.

A monolithic solid PEG matrix limits MMF release to under 2.5% per minute, reducing gastrointestinal concentration peaks and irritation.

Adding paraxanthine to decaffeinated or partially decaffeinated coffee targets wakefulness while reducing caffeine-linked anxiety and irritability.

Excipients and coating materials form cannabis extract pellets that sustain release for 6–7 hours, reducing peak-dose and dependency concerns.

Continuous droplet formation and dehydration control particle circularity, density, and internal void spaces for therapeutic biologics.

Chemically modified aptamers bind HNRPU proteins with high specificity while improving nuclease resistance and cancer-cell internalization.

Micronized budesonide in a CMC-stabilized aqueous suspension extends ocular anti-inflammatory action while reducing frequent applications.

Using 10–500 nm charged nanobubbles creates tissue contact with pathogens and improves the antibacterial effect of medical treatment.

Poorly soluble xanthine oxidase inhibitors are paired with organic bases to improve dissolution, absorption, and bioavailability.

Poorly soluble C66 is dispersed with pharmaceutical carriers to improve dissolution, stability, and oral bioavailability by 6.66 times.

Fibroin nanoparticles shield oral vaccine antigens from gastric acid and enzymes, enabling intestinal delivery and IgA and IgG responses.

Double filtration with a 0.4–0.5 µm membrane, surfactant, and cyclodextrin limits aggregation in stable nasal peptide powder.

Non-protein excipients stabilize fragile Clostridial toxins while avoiding protein-excipient risks such as infectious agent transmission.

Phenotypic selection of CD105+/CD166+ and low-CD45+ MSCs supports uniform expansion, cryopreservation, and consistent therapeutic effects.

A gradual conduit transition and sliding securement connector reduce dead space, turbulence, and leakage in medical fluid delivery.

Self-assembling mannan nanogels target CD206 receptors on dendritic cells for neoepitope delivery while limiting systemic side effects.

Specific plant extracts and sodium, magnesium, and potassium ions regulate goblet cell granules to reduce mucus secretion.

Targeted ARSA mutations increase sulfatide-metabolizing activity, helping address CNS delivery limits while reducing required enzyme doses.

See how tPA–antioxidant nanoconjugates localize at embolic sites to sustain thrombolysis and limit oxidative reperfusion injury.

Buoyant controlled-release particles stay in the bladder to sustain local drug levels, disrupt biofilms, and limit systemic exposure during UTI therapy.

The adapter uses a cap-receiving cavity and narrower container recess to position dispensing containers in a planetary mixer.

The case combines albumin nanoparticles with anti-CD20 antibodies to improve lymphoma targeting, cytotoxicity, and progression-free survival.